Experimental anti-arrhythmic drug reduces death rate in patients with atrial fibrillation
Wednesday, February 18, 2009 - 07:21
in Health & Medicine
Results from the ATHENA trial, reported in the 12th February issue of the New England Journal of Medicine, suggest that the (as yet unlicensed) anti-arrhythmic drug dronedarone can reduce the incidence of cardiovascular-related hospitalisation or death in patients with atrial fibrillation. The study was performed at more than 550 centres in 37 countries...